Strangles is characterized by abscessation of the lymph nodes of the head and neck and is of significant welfare and economic importance. The development of effective preventative vaccines has been slow. A non-encapsulated strain of S. equi (Pinnacle IN™) has been used as a nasal vaccine against strangles, but has not been licensed for sale in Europe due to safety concerns. A second live attenuated vaccine was marketed in Europe 1 (Equilis StrepE), but was withdrawn in 2007. Safety concerns have also been raised over the use of Equilis StrepE 2, 3 . A safe and effective vaccine is thus highly desired.
S. equi evolved from an ancestral strain of S. equi subsp. zooepidemicus (S.
zooepidemicus). The population of the S. zooepidemicus group is extremely diverse and consists of at least 219 sequence types, whereas isolates of S. equi are either ST-179 or a single locus variant, ST-151 that are characteristic of S. equi isolates from the USA, Canada, Australia and Europe 4 (http://pubmlst.org/szooepidemicus/). The limited genetic diversity of S. equi suggests that an effective vaccine could confer broad protection to horses throughout the world.
Access to the genome sequence data of bacterial pathogens permitting the identification of surface exposed and secreted proteins has long been anticipated to revolutionize vaccine design, referred to as reverse vaccinology 5, 6 . However, few vaccines have been taken beyond studies in mouse model systems and shown to confer protection against challenge infection in the natural host. Infection by S. equi leads to an increase in blood fibrinogen and neutrophil levels. As shown in Figure 3 a and b, fibrinogen and neutrophil levels of vaccinated ponies remained normal, whereas the non-vaccinated group had significantly higher mean values.
To minimize suffering and in accordance with our strict ethical and welfare code, ponies were euthanized as soon as clinical signs of S. equi infection became apparent.
All of the control ponies were euthanized between 8 to 12 days post challenge.
Vaccinated horses, however, had reduced clinical signs and all ponies reached the end of the study, 21 days post challenge. Following euthanasia, all of the ponies were subject to post mortem examination to quantify the level of pathology observed using a scoring system as described in Methods.
In a separate study, seven ponies were immunized with a Pentavacc formulation, containing the same antigens as in Septavacc with the exception of IdeE and IdeE2, and then challenged S. equi. Although the Pentavacc ponies differed from the corresponding control group in terms of elevated temperature, fibrinogen levels and nasal discharge, this was not statistically significant. One pony was fully protected. equi in the control and vaccine groups respectively (p=0.004).
Taking all of the results together, vaccination with Septavacc resulted in 85%
protection from disease, with only one vaccinated pony out of seven being infected.
In a study by Timoney et al, 18 two combinations of recombinant extracellular proteins derived from S. equi (SzPSe, CNE, Se51.9, Se44.2 and Se46.8 or SeM, Se44.2, Se75.3, Se42.0, Se110.0 and Se18.9) were tested as vaccines against strangles. However, neither combination protected horses from infection by S. equi 18 .
Two of these proteins CNE and IdeE2 (Se44.2) are included in the Septavacc vaccine, suggesting that the additional components of Septavacc are important in generating a protective immune response. It was also suggested that an effective strangles vaccine should result in immune-mediated tonsillar clearance since tonsillar adherence is a crucial early step in the pathogenesis of strangles 18 , 19 . Thus, the route of immunization and choice of adjuvant, which differ between these studies, might be of utmost importance, an issue to be further addressed in our future studies. It should be noted that mice immunized by the intranasal route are far better protected than those immunized subcutaneously (data not shown).
S. equi shares >80% sequence identity with Streptococcus pyogenes 13 
METHODS

Cloning and production of recombinant antigens.
Antigens used in the vaccination studies were cloned and expressed in Escherichia coli (Supplementary methods).
Mouse model of strangles
Mice were immunized with recombinant antigens followed by experimental infection with S. equi. Infection was assessed by nasal colonization and weight loss 29, 7 (Supplementary Methods).
Immunization of ponies
Healthy 
Experimental infection of ponies
Ponies were transferred to a containment unit three days before challenge. Two weeks after the final booster immunization, each pony was challenged with S. equi strain 4047 administered via the spraying of a 2 ml culture containing 5x10 7 cfu into each nostril. Bacteria were grown overnight in Todd Hewitt broth and 10% foetal calf serum (THBS) in a 5% carbon dioxide enriched atmosphere at 37 o C, diluted 40-fold in fresh pre-warmed THBS, further cultivated and harvested at an OD=0.3. This infection dose has been shown to optimize the infection rate, whilst avoiding overwhelming the host immune response, as determined in previous studies 11, 30 .
Clinical evaluation of and sampling from ponies
Ponies were monitored for the onset of clinical signs of disease over a period of three weeks post challenge by daily physical examination, rectal temperature, lymph node swelling and nasal discharge scoring. Blood samples were taken for evaluation of fibrinogen concentration as described in 11 and neutrophil levels by total white blood count performed on Beckman-Coulter ACTdiff analyser with a manual differential count to calculate % neutrophils. Post mortem score. Ponies were vaccinated with three different antigen combinations, (Trivacc, Pentavacc and Septavacc) followed by challenge with S. equi. Post mortem scoring was performed using a scoring system described in Methods. Non-vaccinated (open symbols) and vaccinated (closed symbols).
